JPRN-UMIN000000661已完成未知
A phase II study on TS-1 treatment for aged patients (<=75 years old) with advanced and/or recurrent gastric cancer (OGSG 0404) - OGSG0404
Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)0 个研究点目标入组 35 人开始时间: 2007年4月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
The response rate (RR) was 14.3% and the median overall survival was 14.6 months.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. with active double cancer 2. with severe other diseases(intestinal paralysis, ileus, intersitial pneumonitis or plumonary fibrosis, uncontrolled DM, cardiac failure, renal dysfunction, liver dysfunction, respiratory dysfunction) 3. severe ascites and/or pulmonary fluid 4. metastasis on central nerve system with symptom 5. fresh bleeding on digestive tract 6. with severe ischemic cardiac disease which needs treatment 7. hypersensitive response to TS-1 8. with severe bone marrow supplession, renal dysfunction or liver dysfunction 9. under administration of flucytosine 10. patients who underwent postoperative adjuvant chemotherapy of TS-1 11. doctor's exclusion due to some reason
研究者
相似试验
已完成
2 期
Phase ll trial of TS-1 + CDDP + Trastuzumab (SPT) - 3 weekly schedule in HER2-positive advanced gastric cancer without measurable metastatic lesion (HERBIS-1B) (OGSG 1202)Advanced Gastric CancerJPRN-UMIN000007941Osaka Gastrointestinal cancer chemotherapy Study Group (OGSG)15
已完成
不适用
A phase II study of S-1 therapy for advanced/recurrent esophageal cancer resistant/intolerable to 5-FU, Platinum compounds, and Taxane (OGSG1404)Esophageal carcinomaJPRN-UMIN000016830Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)17
已完成
1 期
A Phase I Study of TS-142 in Healthy Participants (Single Doses)Healthy VolunteerNCT04169893Taisho Pharmaceutical Co., Ltd.32
已完成
2 期
Randomized phase II study of TS-1/CPT-11 versus TS-1/TXL in advanced/recurrent gastric cancer (OGSG 0402)advanced/recurrent gastric cancerJPRN-UMIN000000638Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)102
已完成
2 期
Phase II trial of SPM-011 + BNCT30 for recurrent malignant gliomaRecurrent malignant gliomaJPRN-jRCT2080224670STELLA PHARMA CORPORATIO27